TB/FLU-01L*

Phase of Development

Inactive/No longer in development

Vaccine Platform

Viral Vector

Candidate Overview

Replication-deficient recombinant influenza virus A expressing ESAT-6 antigen.

Sponsor / Lead Developer: Research Institute for Biological Safety Problems (RIBSP)

Development partner(s): Smorodintsev Research Institute of Influenza (SRII)

Clinical Trials

COMPLETED TRIALS
Registry NumberNCT06873282
Clinical Trial PhasePhase 2
Clinical Trial SponsorResearch Institute of Influenza
Primary endpoint(s) for this clinical trialImmunogenicity
Target population(s) for clinical trialAdults
_________________________
Registry NumberNCT05945498
Clinical Trial PhasePhase 1
Clinical Trial SponsorResearch Institute of Influenza
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults

Source: Vaccine sponsor; ClinicalTrials.gov registry; Online search

Date Updated/Reviewed: 01-Jul-2022